Astrana Health earnings release, May 7, 2026
Astrana Health, Inc. Reports First Quarter
2026 Results
Company to Host Conference Call on Thursday,
May 7, 2026, at 2:30 p.m. PT/5:30 p.m. ET
ALHAMBRA, Calif.,
May 7, 2026
/PRNewswire/
-- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”)
(NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2026.
“We had a strong start to 2026, delivering disciplined growth, strong medical cost performance, continued operating leverage, and early performance from new full-risk contracts in line with our expectations,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “In an increasingly dynamic healthcare environment, we believe advantage will accrue to organizations that can integrate care delivery, data, and financial accountability into a single operating system. Astrana has built exactly that: a proprietary healthcare operating platform that enables us to embed AI and workflow orchestration directly into clinical and operational workflows across the enterprise. Combined with our longitudinal patient relationships and data continuity, our infrastructure allows us to translate AI into durable clinical and economic value while continuing to improve patient outcomes, operating efficiency, and scalability. We believe Astrana is well positioned to continue widening that advantage over time.”
Financial Highlights for First Quarter Ended March 31, 2026:
All comparisons are to the three months ended
March 31, 2025 unless otherwise stated.
(1)
See “Reconciliation of Net Income to EBITDA,
Adjusted EBITDA and Adjusted EBITDA Margin” and “Use of Non-GAAP Financial Measures” below for additional information.
(2)
See reconciliation provided with the condensed consolidated statements of cash flow and “Use of Non-GAAP Financial Measures” below for additional information.
(3)
See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information.
Recent Operating Highlights
Segment Results for three months ended March 31,
2026:
All comparisons are to the three months ended
March 31, 2025 unless otherwise stated.
(1)
Loss from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table.
2026 Guidance:
Astrana is providing the following guidance for total revenue and Adjusted EBITDA for the quarter ending June 30, 2026 and reiterating guidance for the year ending December 31,
2026 based on the Company’s existing business, current view of existing market conditions, and assumptions.
Financial statements
Income Statement
Three Months Ended March 31, 2026 — All comparisons are to the three months ended March 31, 2025 unless otherwise stated. (in thousands)
| Three Months Ended March 31, 2026 – Care Partners | Three Months Ended March 31, 2026 – Care Delivery | Three Months Ended March 31, 2026 – Care Enablement | Three Months Ended March 31, 2026 – Intersegment Elimination | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2026 – Corporate Costs | Three Months Ended March 31, 2026 – Consolidated Total | |
|---|---|---|---|---|---|---|---|
| Total revenues | 909,703 | 85,077 | 87,745 | -117,425 | ) | $— | 965,100 |
| % change vs. prior year quarter | 51.0% | 155.0% | 122.0% | ||||
| Cost of services | 785,531 | 72,544 | 48,704 | -47,423 | ) | 859,356 | |
| General and administrative expenses | 72,546 | 14,374 | 17,259 | -69,974 | ) | 27,532 | 61,737 |
| Depreciation and amortization | 12,170 | 1,122 | 1,629 | 558 | 15,479 | ||
| Total expenses | 870,247 | 88,040 | 67,592 | -117,397 | ) | 28,090 | 936,572 |
| Income (loss) from operations | 39,456 | -2,963 | 20,153 | -28 | -1 | -28,090 | 28,528 |
| % change vs. prior year quarter | -11.0% | -5.0% | 470.0% |
Income Statement
Three Months Ending June 30, 2026 (in millions)
| Three Months Ending June 30, 2026 – Guidance Range – Low | Three Months Ending June 30, 2026 – Guidance Range – High | Year Ending December 31, 2026 – Guidance Range – Low | Year Ending December 31, 2026 – Guidance Range – High | |
|---|---|---|---|---|
| Total revenue | 965 | 1,000 | 3,800 | 4,100 |
| Adjusted EBITDA | 65 | 70 | 250 | 280 |
| Free cash flow | 105 | 132.5 |
Income Statement
Three Months Ended March 31, — (UNAUDITED) (in thousands)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Revenue | Capitation, net | 892,908 | 583,963 |
| Revenue | Risk pool settlements and incentives | 12,486 | 14,491 |
| Revenue | Management fee income | 15,685 | 2,310 |
| Revenue | Fee-for-service, net | 37,831 | 14,890 |
| Revenue | Other revenue | 6,190 | 4,736 |
| Revenue | Total revenue | 965,100 | 620,390 |
| Operating expenses | Cost of services, excluding depreciation and amortization | 859,356 | 549,061 |
| Operating expenses | General and administrative expenses | 61,737 | 43,897 |
| Operating expenses | Depreciation and amortization | 15,479 | 6,849 |
| Operating expenses | Total expenses | 936,572 | 599,807 |
| Operating expenses | Income from operations | 28,528 | 20,583 |
| Other (expense) income | Income (loss) from equity method investments | 1,720 | -867 |
| Other (expense) income | Interest expense | -16,101 | -7,308 |
| Other (expense) income | Interest income | 3,816 | 2,312 |
| Other (expense) income | Unrealized gain (loss) on investments | 1,084 | -44 |
| Other (expense) income | Other income (loss) | 662 | -5,072 |
| Other (expense) income | Total other expense, net | -8,819 | -10,979 |
| Other (expense) income | Income before provision for income taxes | 19,709 | 9,604 |
| Other (expense) income | Provision for income taxes | 6,578 | 3,383 |
| Other (expense) income | Net income | 13,131 | 6,221 |
| Other (expense) income | Net loss attributable to non-controlling interests | -1,305 | -471 |
| Other (expense) income | Net income attributable to Astrana Health, Inc. | 14,436 | 6,692 |
| Other (expense) income | Earnings per share – basic | 0.3 | 0.14 |
| Other (expense) income | Earnings per share – diluted | 0.29 | 0.14 |
| Other (expense) income | Weighted average shares of common stock outstanding – basic | 48,853,678 | 48,470,682 |
| Other (expense) income | Weighted average shares of common stock outstanding – diluted | 49,054,135 | 48,850,666 |
Income Statement
Three Months Ended March 31, (in thousands)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|---|
| Net income | 13,131 | 6,221 | ||
| Interest expense | 16,101 | 7,308 | ||
| Interest income | -3,816 | ) | -2,312 | ) |
| Provision for income taxes | 6,578 | 3,383 | ||
| Depreciation and amortization | 15,479 | 6,849 | ||
| EBITDA | 47,473 | 21,449 | ||
| (Income) loss from equity method investments | -1,720 | ) | 867 | |
| Other, net | 10,650 | -1 | 6,259 | -2 |
| Stock-based compensation | 9,895 | 7,811 | ||
| Adjusted EBITDA | 66,298 | 36,386 | ||
| Total revenue | 965,100 | 620,390 | ||
| Adjusted EBITDA margin | 7 | % | 6 | % |
Income Statement
Three Months Ended March 31, (in thousands, except for share and per share data)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, | Three Months Ended March 31, – 2025 | |
|---|---|---|---|
| Net income | 13,131 | 6,221 | |
| (Income) loss from equity method investments | -1,720 | ) | 867 |
| Other, net (1) | 10,650 | 6,259 | |
| Stock-based compensation | 9,895 | 7,811 | |
| Amortization of intangible assets attributable to acquisitions | 13,850 | 6,263 | |
| Tax adjustments | -7,525 | -2 | -4,602 |
| Adjusted net income attributable to non-controlling interests | -1,928 | -4 | -2,317 |
| Adjusted net income attributable to Astrana Health, Inc. | 36,353 | 20,502 | |
| Weighted average shares of common stock outstanding – diluted | 49,054,135 | 48,850,666 | |
| Adjusted earnings per share - diluted | 0.74 | 0.42 |
Income Statement
Year Ending December 31, 2026 — Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA (in thousands)
| Year Ending December 31, 2026 – Guidance Range – Low | Year Ending December 31, 2026 – Guidance Range – High | |
|---|---|---|
| Net income | 54,000 | 74,000 |
| Interest expense | 51,000 | 55,000 |
| Provision for income taxes | 38,000 | 44,000 |
| Depreciation and amortization | 65,000 | 65,000 |
| EBITDA | 208,000 | 238,000 |
| Income from equity method investments | -4,000 | -4,000 |
| Other, net | 7,000 | 7,000 |
| Stock-based compensation | 39,000 | 39,000 |
| Adjusted EBITDA | 250,000 | 280,000 |
Balance Sheet
March 31, 2026 — (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
| March 31, 2026 – (Unaudited) | December 31, 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 478,383 | 429,474 |
| Current assets | Receivables, net (including amounts from related parties) | 467,395 | 374,465 |
Cash Flow
Three Months Ended March 31, — (UNAUDITED) (in thousands)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|---|
| Cash flows from operating activities | Net income | 13,131 | 6,221 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 15,479 | 6,849 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of debt issuance cost | 1,134 | 691 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Share-based compensation | 9,895 | 7,811 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Non-cash lease expense | 2,005 | 1,287 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred tax | 1,907 | -358 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Change in fair value of contingent consideration liabilities | 581 | 1,407 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Other | -2,564 | ) | 729 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Changes in operating assets and liabilities, net of business combinations | 26,488 | -8,010 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Net cash provided by operating activities | 68,056 | 16,627 | |
| Cash flows from investing activities | Purchases of property and equipment | -4,000 | ) | -3,070 |
| Cash flows from investing activities | Other | 1,156 | 676 | |
| Cash flows from investing activities | Net cash used in investing activities | -2,844 | ) | -2,394 |
| Cash flows from financing activities | Dividends paid | -104 | ) | -5,455 |
| Cash flows from financing activities | Borrowings on debt | 412,000 | ||
| Cash flows from financing activities | Repayment of debt | -11,967 | ) | -428,232 |
| Cash flows from financing activities | Deferred financing cost | -17,241 | ||
| Cash flows from financing activities | Taxes paid from net share settlement of restricted stock | -1,172 | ) | -4,052 |
| Cash flows from financing activities | Repurchase of treasury shares | -2,906 | ) | |
| Cash flows from financing activities | Other | 189 | -1,190 | |
| Cash flows from financing activities | Net cash used in financing activities | -15,960 | ) | -44,170 |
| Cash flows from financing activities | Net increase (decrease) in cash, cash equivalents, and restricted cash | 49,252 | -29,937 | |
| Cash flows from financing activities | Cash, cash equivalents, and restricted cash, beginning of period | 434,045 | 289,101 | |
| Cash flows from financing activities | Cash, cash equivalents, and restricted cash, end of period | 483,297 | 259,164 | |
| Supplemental disclosures of cash flow information | Cash paid for income taxes | -1 | 4,338 | |
| Supplemental disclosures of cash flow information | Cash paid for interest | 14,723 | 7,360 | |
| Supplemental disclosures of non-cash investing and financing activities | Right-of-use assets obtained in exchange for operating lease liabilities | 350 | 5,729 |
Cash Flow
Three Months Ended March 31, — Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | |
|---|---|---|
| Net cash provided by operating activities | 68,056 | 16,627 |
| Purchases of property and equipment | -4,000 | -3,070 |
| Free cash flow | 64,056 | 13,557 |
Cash Flow
Year Ending December 31, 2026 — Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (in thousands)
| Year Ending December 31, 2026 – Guidance Range – Low | Year Ending December 31, 2026 – Guidance Range – High | |
|---|---|---|
| Net cash provided by operating activities | 125,000 | 145,000 |
| Cash used in purchases of property and equipment | -20,000 | -12,500 |
| Free cash flow | 105,000 | 132,500 |
Full release
See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.
Conference Call and Webcast Information:
Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, May 7,
2026), during which management will discuss the results of the first quarter ended March 31,
2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:
The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=HHhCPjaF
An accompanying slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website ( https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana’s current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.
Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company’s consolidated statements of income.
About Astrana Health, Inc.
Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.
Today, Astrana supports more than 20,000 providers and approximately 1.55 million patients in value-based care arrangements through its affiliated provider... (truncated). Together,
Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s guidance for the quarter ending June 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31,
2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statements made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
FOR MORE INFORMATION, PLEASE CONTACT:
Carolyne Sohn, Investor Relations investors@astranahealth.com